History and clinical profile of MYLOTARG: 2 informative videos

Celebrating a transformative journey in AML

Learn more about the clinical journey of MYLOTARG from its initial approval in 2000, its voluntary withdrawal from the market in 2010, and the approval with new indications and fractionated dosing regimen in 2017.

Advancing the treatment of CD33-positive AML

Learn more about EFS, the fractionated dosing regimen of MYLOTARG in combination with chemotherapy, and the efficacy and safety profile of MYLOTARG for adult patients with newly diagnosed, de novo CD33-positive AML.